Literature DB >> 2556648

Effects of an N-methyl-D-aspartate receptor agonist and its antagonist CPP on the levels of dopamine and serotonin metabolites in rat striatum collected in vivo by using a brain dialysis technique.

H Kabuto1, I Yokoi, K Mizukawa, A Mori.   

Abstract

3-((+-)-2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) is an antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. In the present study, levels of dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxyindolacetic acid (5-HIAA) were measured after intracerebroventricular injection of NMDA, CPP or both in rat striatum using a brain dialysis method. The injection of NMDA produced a significant increase in DOPAC level. HVA level was also increased by NMDA injection. The level of 5-HIAA was not affected by NMDA injection. The injection of CPP had no effect on DOPAC, HVA and 5-HIAA levels. The injection of CPP restrained the increase of DOPAC and HVA levels induced by NMDA injection. The results suggest that intracerebral injection of NMDA may increase dopamine release from rat striatum, but have no effect on serotonin release. Furthermore, CPP inhibits NMDA induced release of dopamine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556648     DOI: 10.1007/BF00965613

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  31 in total

1.  Effects of l-glutamate and related amino acids upon the release of [3H]dopamine from rat striatal slices.

Authors:  P J Roberts; N A Sharif
Journal:  Brain Res       Date:  1978-11-24       Impact factor: 3.252

2.  Effect of intraventricular injection of N-methylated GABA-derivatives on the central nervous system of conscious mice.

Authors:  T KITA; H KAMIYA; C KIYOTA
Journal:  Biochem Pharmacol       Date:  1963-02       Impact factor: 5.858

3.  A glutamatergic corticostriatal path?

Authors:  P L McGeer; E G McGeer; U Scherer; K Singh
Journal:  Brain Res       Date:  1977-06-10       Impact factor: 3.252

Review 4.  Excitatory amino acid transmitters.

Authors:  J C Watkins; R H Evans
Journal:  Annu Rev Pharmacol Toxicol       Date:  1981       Impact factor: 13.820

5.  Characterization of the excitatory amino acid receptor-mediated release of [3H]acetylcholine from rat striatal slices.

Authors:  J Lehmann; B Scatton
Journal:  Brain Res       Date:  1982-12-02       Impact factor: 3.252

6.  The effect of omega-phosphono-alpha-aminocarboxylic acids on seizures and brain amino acid levels in E1 mice.

Authors:  M Shimada; H Kabuto; I Yokoi
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-09

7.  CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo.

Authors:  J Lehmann; J Schneider; S McPherson; D E Murphy; P Bernard; C Tsai; D A Bennett; G Pastor; D J Steel; C Boehm
Journal:  J Pharmacol Exp Ther       Date:  1987-03       Impact factor: 4.030

8.  Stimulatory effect of L-glutamate and related amino acids on [3H]dopamine release from rat striatum: an in vitro model for glutamate actions.

Authors:  P J Roberts; S D Anderson
Journal:  J Neurochem       Date:  1979-05       Impact factor: 5.372

9.  Characterization of the inhibition of excitatory amino acid-induced neurotransmitter release in the rat striatum by phencyclidine-like drugs.

Authors:  L D Snell; K M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

10.  Differences between the release of radiolabelled and endogenous dopamine from superfused rat brain slices: effects of depolarizing stimuli, amphetamine and synthesis inhibition.

Authors:  H Herdon; J Strupish; S R Nahorski
Journal:  Brain Res       Date:  1985-12-02       Impact factor: 3.252

View more
  7 in total

1.  Effect of NMDA receptor antagonists on D1, D2 and D1/D2 mediated behaviors in intact rats.

Authors:  R Dall'Olio; R Rimondini; O Gandolfi
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra.

Authors:  K Wedzony; A Czyrak; M Maćkowiak; K Fijał
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

3.  The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents.

Authors:  L J Bristow; P H Hutson; L Thorn; M D Tricklebank
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

4.  Further contribution to the study of corticostriatal glutamatergic and nigrostriatal dopaminergic interactions within the striatal network: an in vivo voltammetric investigation.

Authors:  C Forni; N Dusticier; A Nieoullon
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

5.  2-Guanidinoethanol increased dopamine release and 3,4-dihydroxyphenylacetic acid content, but not homovanillic acid content in the rat brain: electroneurochemical and enzymological studies.

Authors:  I Yokoi; H Kabuto; K Hukuyama; Y Nishijima; T Itoh; K Yufu; K Akiyama; A Mori
Journal:  Neurochem Res       Date:  1992-07       Impact factor: 3.996

6.  Monoamine metabolites, iron induced seizures, and the anticonvulsant effect of tannins.

Authors:  H Kabuto; I Yokoi; A Mori
Journal:  Neurochem Res       Date:  1992-06       Impact factor: 3.996

7.  Effects of kainic acid, quisqualic acid, and their antagonist, pCB-PzDA, on rat electrocorticograms and monoamine metabolite levels in rat striatum.

Authors:  H Kabuto; I Yokoi; S MoonSuk; M Yamamoto; A Mori
Journal:  Neurochem Res       Date:  1994-03       Impact factor: 3.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.